[1] |
XU Rui, WANG Zehao, WU Jiong.
Advances in the role of tumor-associated neutrophils in the development of breast cancer
[J]. China Oncology, 2024, 34(9): 881-889.
|
[2] |
CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong.
The progress of treatment for brain metastases of triple-negative breast cancer
[J]. China Oncology, 2024, 34(8): 777-784.
|
[3] |
ZHANG Jian.
Clinical consideration of two key questions in assessing menopausal status of female breast cancer patients
[J]. China Oncology, 2024, 34(7): 619-627.
|
[4] |
JIANG Dan, SONG Guoqing, WANG Xiaodan.
Study on the mechanism of mitochondrial dysfunction and CPT1A/ERK signal transduction pathway regulating malignant behavior in breast cancer
[J]. China Oncology, 2024, 34(7): 650-658.
|
[5] |
DONG Jianqiao, LI Kunyan, LI Jing, WANG Bin, WANG Yanhong, JIA Hongyan.
A study on mechanism of SIRT3 inducing endocrine drug resistance in breast cancer via deacetylating YME1L1
[J]. China Oncology, 2024, 34(6): 537-547.
|
[6] |
HAO Xian, HUANG Jianjun, YANG Wenxiu, LIU Jinting, ZHANG Junhong, LUO Yubei, LI Qing, WANG Dahong, GAO Yuwei, TAN Fuyun, BO Li, ZHENG Yu, WANG Rong, FENG Jianglong, LI Jing, ZHAO Chunhua, DOU Xiaowei.
Establishment of primary breast cancer cell line as new model for drug screening and basic research
[J]. China Oncology, 2024, 34(6): 561-570.
|
[7] |
Committee of Breast Cancer Society, China Anti-Cancer Association.
Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer (2024 edition)
[J]. China Oncology, 2024, 34(3): 316-333.
|
[8] |
ZHANG Qi, XIU Bingqiu, WU Jiong.
Progress of important clinical research of breast cancer in China in 2023
[J]. China Oncology, 2024, 34(2): 135-142.
|
[9] |
ZHANG Siyuan, JIANG Zefei.
Important research progress in clinical practice for advanced breast cancer in 2023
[J]. China Oncology, 2024, 34(2): 143-150.
|
[10] |
WANG Zhaobu, LI Xing, YU Xinmiao, JIN Feng.
Important research progress in clinical practice for early breast cancer in 2023
[J]. China Oncology, 2024, 34(2): 151-160.
|
[11] |
LUO Yang, SUN Tao, SHAO Zhimin, CUI Jiuwei, PAN Yueyin, ZHANG Qingyuan, CHENG Ying, LI huiping, YANG Yan, YE Changsheng, YU Guohua, WANG Jingfen, LIU Yunjiang, LIU Xinlan, ZHOU Yuhong, BAI Yuju, GU Yuanting, WANG Xiaojia, XU Binghe, SONG Lihua.
Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial
[J]. China Oncology, 2024, 34(2): 161-175.
|
[12] |
CHEN Yuanxiang, YU Tao, YANG Shiyu, ZENG Tao, WEI Lan, ZHANG Yan.
KDM4A promotes the migration and invasion of breast cancer cell line MDA-MB-231 by downregulating BMP9
[J]. China Oncology, 2024, 34(2): 176-184.
|
[13] |
HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda.
Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer
[J]. China Oncology, 2024, 34(2): 185-190.
|
[14] |
ZHANG Siwei, MA Ding, JIANG Yizhou, SHAO Zhimin.
“Subtype-precise” therapy leads diagnostic and therapeutic innovations: a new pattern for precision treatment of breast cancer
[J]. China Oncology, 2024, 34(11): 1045-1052.
|
[15] |
XU Ziqi, HU Ruizhi, LI Junjian, WANG Hongxia, SANG Youzhou.
Exploring the role of methylation-driven gene IFFO1 in pancreatic adenocarcinoma diagnosis, prognosis and cellular functions
[J]. China Oncology, 2024, 34(11): 998-1010.
|